Search

AVAC Board Member Jeanne Marrazzo named CEO of IDSA 

AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new chief executive officer of the Infectious Diseases Society of America (IDSA).

AVAC Board Member Jeanne Marrazzo named CEO of IDSA 

AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new chief executive officer of the Infectious Diseases Society of America (IDSA).

The Future of HIV Prevention Depends on Speed, Scale and Equity 

We are in a golden moment, where innovation, evidence and opportunity align. But proposed funding cuts could undo everything. These aren’t abstract numbers on a page. These cuts would shutter clinics, slow prevention, restrict treatment, and roll back the very systems that allow new tools like LEN to reach people.

STIWatch Quarterly Newsletter

As many global health fields reassess their reliance on US government funding for research and development, the STI field—already underfunded and reliant on alternate donors—now faces even greater uncertainty. In this newsletter, we share a new STI resource for advocates and highlight the top issues we’re monitoring as events continue to unfold.

Conference on Retroviruses and Opportunistic Infections (CROI 2026)

People’s Research Agenda

The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

Multipurpose Prevention Technologies (MPTs) Studies Halted by USAID Funding Termination

This graphic shows a list of which studies have been halted by eliminated USAID funding.

At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

HIV Prevention Pipeline: Products to Watch

From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.

People’s Research Agenda Pipeline Tracker

This tracker provides details on key HIV prevention trials to watch. It is updated on a quarterly and ad-hoc basis as developments occur.